LONDON, 8 September 2026 – Premialab, the leading independent platform for quantitative analytics and quantitative investment strategies, and Parameta Solutions, a world-leading provider of OTC market data, analytics, and post-trade solutions, today announced a partnership that will integrate Parameta Solutions’ index family into Premialab’s quantitative analytics platform.
The integration will give institutional investors access to Parameta Solutions’ indices within Premialab’s independent research and analytics environment, combining transparent, market-driven benchmarks with advanced quantitative analysis.
Parameta Solutions’ indices, covering swap rates, interest rate volatility, inflation swaps and global LNG basis will be available within Premialab’s research and analysis environment, giving institutional investors greater access to benchmarks across rates and commodities markets.
Adrien Géliot, CEO of Premialab, said:
“We are delighted to integrate Parameta Solutions’ indices into Premialab. As systematic strategies play an increasingly important role in rates and commodities markets, institutional investors need access to high-quality, transparent benchmarks alongside robust performance analytics. This integration brings together Parameta’s indices with Premialab’s analytics, providing our clients with a comprehensive toolkit for systematic strategy analysis.”
Silvina Aldeco-Martinez, CEO of Parameta Solutions, said:
“High-quality benchmarks are most valuable when they are easy to analyse and use. Many of the world’s leading macro and systematic strategies rely on signals from OTC rates and commodities markets. By integrating our indices into Premialab, we are making it simpler for institutional investors to access transparent benchmarks derived from those markets and evaluate them through an independent analytical lens.”
Clients using Premialab will be able to analyse Parameta Solutions’ indices using Premialab’s independent analytics suite, including its Pure Factors framework, to independently benchmark and analyse index performance. This provides investors with additional tools to assess performance, understand source of risk and return, and evaluate the drivers of systematic strategies.
About Premialab
Premialab is an independent platform that collaborates with investment banks and institutional investors globally, providing data, analytics and risk solutions for systematic, factor and multi-asset strategies. Premialab’s multi-asset, multi-region platform handles over 15 million data points daily across more than 7,000 investable systematic strategies, representing client assets under management of approximately USD 20 trillion. Its proprietary dataset and analytics provide detailed risk decomposition, factor attribution and scenario-based analysis.
With offices in London, Paris, New York, Hong Kong, Dubai and Sydney, the company partners with investment banks, asset managers, pension funds, sovereign wealth funds and insurance companies globally.
About Parameta Solutions
Parameta Solutions is the data and analytics division of the TP ICAP Group and the exclusive provider of OTC market data from TP ICAP’s leading brokerage brands, including ICAP, Tullett Prebon and PVM. We deliver high-quality market data, indices and analytics across energy and commodities, interest rate swaps and options, money markets, and FX, empowering financial professionals worldwide with trusted insights for the creation of trading strategies, price discovery, pre & post trade analytics, risk management, and regulatory compliance.
Disclaimer
© 2026 ICAP Information Services Limited (“IISL”). This communication is provided by ICAP Information Services Limited or a member of its group (“Parameta”) and all information contained in or attached hereto (the “Information”) is for information purposes only and is confidential. Access to the Information by anyone other than the intended recipient is unauthorised without Parameta’s prior written approval. The Information may not be not used or disclosed for any purpose without Parameta’s prior written approval, including without limitation, storing, copying, distributing, licensing, selling or displaying the Information, using the Information in an application or to create derived data of any kind, co-mingling the Information with any other data or using the data for any unlawful purpose of for any purpose that would cause it to become a benchmark under any law, regulation or guidance. The Information is not, and should not be construed as, a live price, an offer, bid, recommendation or solicitation in relation to any financial instrument or investment or to participate in any particular trading strategy or constituting financial or investment advice or a financial promotion. The Information does not constitute a public offer under any applicable legislation or an offer to sell or a solicitation of an offer to buy any securities. The Information is not to be relied upon for any purpose whatsoever and is provided “as is” without warranty of any kind, either expressly or by implication, including without limitation as to completeness, timeliness, accuracy, continuity, merchantability or fitness for any particular purpose. All representations and warranties are expressly disclaimed, to the fullest extent possible under applicable law. In no circumstances will Parameta be liable for any indirect or direct loss, or consequential loss or damages including without limitation, loss of business or profits arising from the use of or any inability to use the Information, or any inaccuracy in the Information. Parameta may suspend, withdraw or modify or change the terms of the provision of the Information at any time in its sole discretion, without notice. All rights, including without limitation intellectual property rights, in and to the Information are, and shall remain, the property of IISL or its licensors. Use of, access to or delivery of Parameta’s products and/or services requires a prior written licence from Parameta or its relevant affiliates. The terms of this disclaimer are governed by the laws of England and Wales.
